Sarah Guzman-Marte
Internal Medicine · New York, NYNPI 1821300179
Payments from drug & device makers
Across 154 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$643
- AbbVie$336
- AstraZeneca$325
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$257
- Astellas Pharma US Inc$202
- Amarin Pharma, Inc.$183
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,214100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $643 |
| AbbVie | 21 | $336 |
| AstraZeneca | 10 | $325 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $257 |
| Astellas Pharma US Inc | 7 | $202 |
| Amarin Pharma, Inc. | 4 | $183 |
| Pfizer | 5 | $135 |
| GSK | 8 | $128 |
| Mannkind Corporation | 1 | $124 |
| Boehringer Ingelheim | 5 | $115 |
| Corcept Therapeutics | 1 | $105 |
| Amgen(2 entities) | 5 | $101 |
| Shield Therapeutics Inc | 4 | $80 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Exact Sciences | 3 | $63 |
| Bayer | 3 | $49 |
| Ardelyx, Inc. | 2 | $46 |
| Merck | 3 | $45 |
| Optos, Inc. | 1 | $39 |
| Lilly USA, LLC | 2 | $37 |
| Johnson & Johnson | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,214 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 329 | $362,039 |
| OzempicSemaglutide | 105 | $111,931 |
| RybelsusSemaglutide | 77 | $105,910 |
| JanuviaSitagliptin Phosphate | 84 | $86,734 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 73 | $73,906 |
| FarxigaDapagliflozin Propanediol | 48 | $52,272 |
| TrulicityDulaglutide | 48 | $49,022 |
| VascepaIcosapent Ethyl | 107 | $47,650 |
| JanumetSitagliptin Phos/Metformin Hcl | 39 | $47,633 |
| LinzessLinaclotide | 70 | $46,819 |
| EliquisApixaban | 49 | $41,351 |
| EntrestoSacubitril/Valsartan | 26 | $39,951 |
| XareltoRivaroxaban | 30 | $25,231 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $24,522 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 78 | $24,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Jentadueto | $115 | $371,047343 claims |
| Novo NordiskOzempic, Rybelsus | $643 | $217,841182 claims |
| MerckJanuvia, Janumet Xr, Janumet, Steglatro | $45 | $213,242209 claims |
| AstraZenecaFarxiga, Lokelma, Symbicort | $325 | $73,978102 claims |
| Lilly USA, LLCTrulicity | $37 | $49,02248 claims |
| AbbVieLinzess | $336 | $46,81970 claims |
| PfizerEliquis | $135 | $41,35149 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $128 | $29,50453 claims |
| Johnson & JohnsonXarelto | $35 | $25,23130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.